Viatris Inc. vs Eli Lilly & Co.
VTRS vs LLY — side-by-side comparison from reported financials. VTRS leads 4, LLY leads 8 of 12 comparable metrics.
Viatris Inc.
VTRS · Healthcare
$17.64+1.15%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | VTRS | LLY |
|---|---|---|
| Price | $17.64 | $1 177.20 |
| Market cap | $20.3B | $1.05T |
| Revenue (TTM) | $14.7B | $79.7B |
| Revenue growth | -4.2% | +31.7% |
| Net margin | -2.8% | 33.5% |
| Free cash flow | $1.95B | $18.2B |
| Net cash (debt) | ($11.2B) | ($35.2B) |
| 1-year price return | +76.6% | +37.6% |
| P/E | 5.5 | 41.6 |
| P/E vs own history (cheap-side %) | 9% | 88% |
| Dividend yield | 2.75% | 0.52% |
| Return on equity | -3% | 93% |
| Altman Z-score | 0.99 | 7.10 |
| CV checks passed | 6 of 11 | 11 of 11 |
| Employees | 30,000 | 50,000 |
Full résumé-style profiles: VTRS CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.